---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-032512"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-10-31T23:59:59+00:00"
generated_at: "2026-05-17T01:06:17.233489+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Robert Ferrara resigns; David Deming appointed Lead Independent Director

## Summary
- Robert Ferrara resigned effective Oct 31, 2025; no disagreement cited.
- Board reduced from 6 to 5 members; no vacancies remain.
- David Deming appointed Lead Independent Director; brings 30+ yrs investment banking (JP Morgan).
- Deming joined Phio Board in Feb 2025; serves on Nominating Committee.

## SEC filing metadata
- accession: 0001437749-25-032512
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-10-31T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000143774925032512/0001437749-25-032512-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000143774925032512/phio20251030_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-032512
- JSON: https://secwatch.observer/filing/0001437749-25-032512.json
- Plain text: https://secwatch.observer/filing/0001437749-25-032512.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.